Target Market Epinoma aims to serve the blood test developer market, presenting a clear entry point for collaboration, product integration, and co-development opportunities with labs and diagnostic providers seeking improved assay performance.

Clinical Pipeline Longer term strategy targets second generation epigenetic medicines, signaling potential partnerships with pharmaceutical companies for research, development, and translational programs that leverage their protein engineering platform.

Tech Differentiator A protein platform enabling reading and writing epigenetic signals can be positioned as a unique capability to enhance biomarker discovery, assay sensitivity, and early disease detection solutions for customers seeking cutting-edge technology.

Growth Readiness Current revenue range indicates early-stage traction; engage strategic customers and investors who can scale with Epinoma as the platform matures, with emphasis on pilots that demonstrate measurable performance gains.

Competitive Landscape Benchmark against established genomics and diagnostics players by highlighting faster turnaround, potential risk reduction, and safety advantages of epigenetic approaches to capture interest from large labs and hospital systems.